Nektar Therapeutics (NKTR) Invested Capital (2011 - 2020)

Nektar Therapeutics' Invested Capital history runs 7 years deep, the most recent figure standing at $254.1 million for Q1 2020.

• On a quarterly basis, Invested Capital changed N/A year-over-year to $254.1 million in Q1 2020; TTM through Dec 2020 was $254.1 million, a 0.5% change from a year earlier, with the FY2019 full-year figure at $252.9 million, changed N/A from the prior year.
• Invested Capital steadied at $254.1 million in Q1 2020 per NKTR's latest filing, from $252.9 million in the prior quarter.
• Across five years, Invested Capital topped out at $254.1 million in Q1 2020 and bottomed at $3.0 million in Q3 2017.
• The 4-year median for Invested Capital is $5.1 million (2016), against an average of $60.3 million.
• Across the five-year window, Invested Capital fell 12.07% in 2016 and plunged 44.44% in 2017, its largest moves.
• Year by year, Invested Capital stood at $5.1 million in 2016, then plunged by 41.18% to $3.0 million in 2017, then soared by 8329.7% to $252.9 million in 2019, then climbed by 0.5% to $254.1 million in 2020.
• Per Business Quant, the three latest NKTR Invested Capital figures stand at $254.1 million (Q1 2020), $252.9 million (Q4 2019), and $3.0 million (Q3 2017).